C4 Therapeutics, Inc. (CCCC) Reports In-Line Q2 EPS

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $12 million versus the consensus estimate of $4.78 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Uber Is Said To Be In Advanced Talks On Delivery Hero Takeover - Bloomberg
• Manpower Inc. (MAN) PT Raised to $41 at UBS Ahead of Q2 Earnings
• Deepseek Is Said To Prepare For Ipo Filing As Soon As This Year - Bloomberg